Alpha 2.0
Login Register
» Authors » Marleen Keyaerts

Marleen Keyaerts

Explore the profile of Marleen Keyaerts including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 61
Citations 1761
Followers 0
Related Specialties
Nuclear Medicine
Oncology
Radiology
Top 10 Co-Authors
Nick Devoogdt
Tony Lahoutte
Karine Breckpot
Vicky Caveliers
Quentin Lecocq
Geert Raes
Catarina Xavier
Matthias DHuyvetter
Hendrik Everaert
Yannick De Vlaeminck
Published In
J Nucl Med
Cancers (Basel)
Mol Imaging Biol
Eur J Nucl Med Mol Imaging
Theranostics
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficient α and β radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model
Ceuppens H, Pombo Antunes A, Navarro L, Ertveldt T, Berdal M, Nagachinta S, et al.
Eur J Nucl Med Mol Imaging . 2024 Sep; 52(2):444-457. PMID: 39237746
Purpose: Targeted radionuclide therapy (TRT) is a cancer treatment with relative therapeutic efficacy across various cancer types. We studied the therapeutic potential of TRT using fibroblast activation protein-α (FAP) targeting...
2.
Generic semi-automated radiofluorination strategy for single domain antibodies: [F]FB-labelled single domain antibodies for PET imaging of fibroblast activation protein-α or folate receptor-α overexpression in cancer
Dierick H, Navarro L, Ceuppens H, Ertveldt T, Pombo Antunes A, Keyaerts M, et al.
EJNMMI Radiopharm Chem . 2024 Jul; 9(1):54. PMID: 39048805
Background: Radiofluorination of single domain antibodies (sdAbs) via N-succinimidyl-4-[F]fluorobenzoate ([F]SFB) has shown to be a promising strategy in the development of sdAb-based PET tracers. While automation of the prosthetic group...
3.
Clinicopathological and molecular predictors of [F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
Llombart-Cussac A, Prat A, Perez-Garcia J, Mateos J, Pascual T, Escriva-de-Romani S, et al.
Eur J Nucl Med Mol Imaging . 2024 Apr; 51(9):2733-2743. PMID: 38587643
Background: The PHERGain study (NCT03161353) is assessing early metabolic responses to neoadjuvant treatment with trastuzumab-pertuzumab and chemotherapy de-escalation using a [Fluorine]fluorodeoxyglucose-positron emission tomography ([F]FDG-PET) and a pathological complete response-adapted strategy...
4.
Optimal [F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, et al.
J Nucl Med . 2024 Apr; 65(5):708-713. PMID: 38575192
The PHERGain trial investigated the potential of metabolic imaging to identify candidates for chemotherapy deescalation in human epidermal growth factor receptor 2 (HER2)-positive, invasive, operable breast cancer with at least...
5.
Phase II Trial Assessing the Repeatability and Tumor Uptake of [Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma
Gondry O, Caveliers V, Xavier C, Raes L, Vanhoeij M, Verfaillie G, et al.
J Nucl Med . 2024 Feb; 65(2):178-184. PMID: 38302159
Human epidermal growth factor receptor 2 (HER2) status is used for decision-making in breast carcinoma treatment. The status is obtained through immunohistochemistry or in situ hybridization. These two methods have...
6.
The Presence of Anti-TPO Antibodies Increase the Likelihood of Post-I131 Hypothyroidism
Quataert F, Bravenboer B, Keyaerts M, Andreescu C
Horm Metab Res . 2023 Nov; 56(2):134-141. PMID: 37931916
The use of radioactive iodine in the treatment of hyperthyroidism is common practice. However, a standardized treatment protocol with regard to radioactive iodine treatment (RAI) remains subject to discussion. We...
7.
Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8 T cell and iNKT cell activating mRNA vaccine
Ertveldt T, Meulewaeter S, De Vlaeminck Y, Olarte O, Broos K, Van Calenbergh S, et al.
Theranostics . 2023 Nov; 13(15):5483-5500. PMID: 37908728
Although promising responses are obtained in patients treated with immune checkpoint inhibitors targeting programmed death ligand 1 (PD-L1) and its receptor programmed death-1 (PD-1), only a fraction of patients benefits...
8.
Development and Validation of a Predictive Model for Metastatic Melanoma Patients Treated with Pembrolizumab Based on Automated Analysis of Whole-Body [F]FDG PET/CT Imaging and Clinical Features
Dirks I, Keyaerts M, Dirven I, Neyns B, Vandemeulebroucke J
Cancers (Basel) . 2023 Aug; 15(16). PMID: 37627111
Background: Antibodies that inhibit the programmed cell death protein 1 (PD-1) receptor offer a significant survival benefit, potentially cure (i.e., durable disease-free survival following treatment discontinuation), a substantial proportion of...
9.
Phase I Study of [Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)
Gondry O, Xavier C, Raes L, Heemskerk J, Devoogdt N, Everaert H, et al.
J Nucl Med . 2023 Jul; 64(9):1378-1384. PMID: 37474271
Macrophages play an important role throughout the body. Antiinflammatory macrophages expressing the macrophage mannose receptor (MMR, CD206) are involved in disease development, ranging from oncology to atherosclerosis and rheumatoid arthritis....
10.
Targeted α-Therapy Using Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, et al.
J Nucl Med . 2023 Apr; 64(5):751-758. PMID: 37055223
Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle-emitting radionuclides (α-TRT) is an intensely investigated treatment approach as the short range of α-particles allows effective treatment of local lesions...